- 20 Years
16 October 2018, 18:00 - 20:30
Deloitte, One Trinity Gardens, Broad Chare, Newcastle upon Tyne NE1 2HF
There is no more ambitious and lofty a goal than empowering people around the world to help control and eradicate disease and reduce suffering, but that’s exactly what Elaine Warburton and her co-founders at QuantuMDx have set out to do from their base on Newcastle’s quayside.
An entrepreneur with over 25 years’ experience in the healthcare and biotechnology sectors, Elaine has taken QuantuMDx from concept to commercialisation in 10 years, raising over £50m in the process.
The result is ‘Q-POC’, a highly innovative portable laboratory that can help personalise medicine by diagnosing disease in minutes at the patient’s side, all for a few dollars.
Q-POC’s simplicity of use and low cost means that anyone, anywhere in the world can be accurately diagnosed with “Gold Standard” laboratory accuracy.
The initial focus of QMDx is detecting the strains of Human Papilloma Virus (HPV) - the causative virus of cervical cancer (and other cancers) - but the implications of a molecular level multi-test like this are huge. With an immediate genetic diagnosis, a bespoke prescription can be issued to ensure medicines can be tolerated, making sure patients are given the right course of treatment; personalising medicine globally.
Through wireless connectivity, Q-POC will be able to coordinate and map data on diseases identified through their tests, spotting potential global pandemics and new strains of disease quickly enough to mobilise health care and therefore control outbreaks early and efficiently.
With Bill Gates, through his Global Good Fund, recently investing to expand the number of tests on the Q-POC, this is one North East success story that is set to change the world for the better.
EXPLORE - how Elaine has raised over £50m through a wide variety of funding sources to innovate and start the commercialisation of Q-POC.
LEARN - why 2019 is shaping up to be a watershed year for QuantuMDx.
GAIN - an understanding of how this pioneering tech firm are changing the face of global medicine.